ProQR Therapeutics N.V. Ordinary Shares (PRQR)
Stock · NASDAQ · Health Care
$1.31as of 10/16/2026
Price chart
Active signals
PRQR Signal Track Record
How signals performed across all stocks →What PRQR's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 36 | -5.2% | 39% | September 23, 2026 |
| Bollinger Band Breakout | 25 | +4.6% | 60% | August 5, 2026 |
| Bollinger Band BreakdownActive now | 15 | +0.5% | 53% | March 27, 2026 |
| 200-Day Moving Average TouchActive now | 14 | +0.0% | 50% | August 10, 2026 |
| Any 20-session window (baseline) | 0.0% | 50% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About PRQR
ProQR Therapeutics N.V., a clinical-stage biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company develops an RNA editing platform through its Axiomer RNA editing technology for genetic disorders with unmet needs. Its lead product candidate, AX-0810, targets na-taurocholate cotransporting polypeptide (NTCP) for the treatment of cholestatic diseases. The company also…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 186
- Website
- www.proqr.com/
Fundamentals
- 1-day range
- $1.34$1.49
- Market cap
- $268.13M
- P/E (trailing)
- —
- P/E (forward)
- -2.88
- EPS (trailing)
- $-0.40
- Dividend yield
- —
- Beta
- 0.21
- Avg. volume
- 826.2K
Forecasts
9 analyst ratings
ProQR Therapeutics N.V. Ordinary Shares Competitors
Chosen by industry and closest market cap.
- PRQRProQR Therapeutics N.V. Ordinary Shares$1.31▼ 9.66%Market cap $268.13MP/E —$1.33$3.1
- ELDNEledon Pharmaceuticals Inc. Common Stock$2.13▼ 6.17%Market cap $267.07MP/E —$1.35$4.6
- TRDAEntrada Therapeutics Inc. Common Stock$4.37▼ 8.58%Market cap $266.70MP/E —$4.11$16.45
- CLLSCellectis S.A. American Depositary Shares$1.04▼ 5.88%Market cap $270.42MP/E —$1.04$4.75
- VRXAVeraxa Biotech AG Ordinary Shares$1.11▲ 0.91%Market cap $263.02MP/E —$1.04$27.36
- ADAGAdagene Inc. American Depositary Shares$2.06▼ 14.17%Market cap $273.45MP/E —$1.3$4.85
- EBSEmergent BioSolutions Inc. Common Stock$6.38▼ 11.14%Market cap $273.98MP/E —$4.36$14.06
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| PRQR ProQR Therapeutics N.V. Ordinary Shares | $268.13M | — | $1.31 | ▼ 9.66% | $1.33$3.1 |
| ELDN Eledon Pharmaceuticals Inc. Common Stock | $267.07M | — | $2.13 | ▼ 6.17% | $1.35$4.6 |
| TRDA Entrada Therapeutics Inc. Common Stock | $266.70M | — | $4.37 | ▼ 8.58% | $4.11$16.45 |
| CLLS Cellectis S.A. American Depositary Shares | $270.42M | — | $1.04 | ▼ 5.88% | $1.04$4.75 |
| VRXA Veraxa Biotech AG Ordinary Shares | $263.02M | — | $1.11 | ▲ 0.91% | $1.04$27.36 |
| ADAG Adagene Inc. American Depositary Shares | $273.45M | — | $2.06 | ▼ 14.17% | $1.3$4.85 |
| EBS Emergent BioSolutions Inc. Common Stock | $273.98M | — | $6.38 | ▼ 11.14% | $4.36$14.06 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- ProQR Reports First Human Validation of RNA Editing Platform in Liver DiseaseYahoo · 10/2/2026
- HC Wainwright & Co. Maintains Buy on ProQR Therapeutics, Lowers Price Target to $8benzinga · 10/1/2026
- HC Wainwright & Co. Maintains Buy on ProQR Therapeutics, Lowers Price Target to $8Benzinga · 10/1/2026
- ProQR Therapeutics N.V. (PRQR) Shareholder/Analyst Call - SlideshowSeekingAlpha · 9/30/2026
- ProQR Therapeutics N.V. (PRQR) Shareholder/Analyst Call TranscriptSeekingAlpha · 9/30/2026
- ProQR Announces Appointment of Chris Hart as Chief Data and AI Officer and Thomas Wolf to join the Board of Directors as Strategic AI AdvisorYahoo · 9/23/2026
Insider Activity
Insider Actions →- de Boer Daniel Anton · July 31, 2026 · Buy200.0K @ $1.77
- Bart Filius · July 17, 2026 · Buy150.0K @ $1.72
- de Boer Daniel Anton · July 9, 2026 · Buy150.0K @ $1.74
- de Boer Daniel Anton · July 7, 2026 · Buy150.0K @ $1.59
- Hinsch Gylvin Lykke · June 2, 2026 · Grant14.5K
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 27, 2026
ProQR Appoints New Chief Data and AI Officer and Board Advisor
ProQR Therapeutics has named Chris Hart as its new Chief Data and AI Officer and added Thomas Wolf to the board as a Strategic AI Advisor. These appointments signal a strategic focus on integrating artificial intelligence into the company's operations. The stock is currently trading near its 52-week low, with the recent leadership changes occurring while the share price remains well below the average analyst target.
ProQR Appoints New Chief Data and AI Officer and Board Advisor. ProQR Therapeutics has named Chris Hart as its new Chief Data and AI Officer and added Thomas Wolf to the board as a Strategic AI Advisor. These appointments signal a strategic focus on integrating artificial intelligence into the company's operations. The stock is currently trading near its 52-week low, with the recent leadership changes occurring while the share price remains well below the average analyst target.